120-W 2-µm thulium:yttrium-aluminium-garnet vapoenucleation of the prostate: 12-month follow-up.
Identifieur interne : 000516 ( Ncbi/Merge ); précédent : 000515; suivant : 000517120-W 2-µm thulium:yttrium-aluminium-garnet vapoenucleation of the prostate: 12-month follow-up.
Auteurs : Christopher Netsch [Allemagne] ; Laura Pohlmann ; Thomas R W. Herrmann ; Andreas J. Gross ; Thorsten BachSource :
- BJU international [ 1464-410X ] ; 2012.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Humains, Hyperplasie de la prostate (), Hyperplasie de la prostate (anatomopathologie), Hyperplasie de la prostate (diagnostic), Lasers à solide (effets indésirables), Lasers à solide (usage thérapeutique), Mâle, Prostate (anatomopathologie), Sujet âgé, Sujet âgé de 80 ans ou plus, Thulium.
- MESH :
- anatomopathologie : Hyperplasie de la prostate, Prostate.
- diagnostic : Hyperplasie de la prostate.
- effets indésirables : Lasers à solide.
- usage thérapeutique : Lasers à solide.
- Adulte d'âge moyen, Humains, Hyperplasie de la prostate, Mâle, Sujet âgé, Sujet âgé de 80 ans ou plus, Thulium.
English descriptors
- KwdEn :
- MESH :
- chemical : Thulium.
- adverse effects : Lasers, Solid-State.
- diagnosis : Prostatic Hyperplasia.
- pathology : Prostate, Prostatic Hyperplasia.
- surgery : Prostatic Hyperplasia.
- therapeutic use : Lasers, Solid-State.
- Aged, Aged, 80 and over, Humans, Male, Middle Aged.
Abstract
Study Type - Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Thulium VapoEnucleation of the prostate (ThuVEP) has been introduced as a minimally invasive treatment modality of benign prostate obstruction (BPO). This study reports the largest series of patients with symptomatic BPO undergoing ThuVEP. Efficacy of this procedure was confirmed by prostate volume and PSA measurements at 12-month follow up, which have not been reported after ThuVEP so far.
DOI: 10.1111/j.1464-410X.2011.10767.x
PubMed: 22085294
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000408
- to stream PubMed, to step Curation: 000408
- to stream PubMed, to step Checkpoint: 000408
Links to Exploration step
pubmed:22085294Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">120-W 2-µm thulium:yttrium-aluminium-garnet vapoenucleation of the prostate: 12-month follow-up.</title><author><name sortKey="Netsch, Christopher" sort="Netsch, Christopher" uniqKey="Netsch C" first="Christopher" last="Netsch">Christopher Netsch</name><affiliation wicri:level="3"><nlm:affiliation>Department of Urology, Asklepios Hospital Barmbek, Hamburg, Germany. c.netsch@asklepios.com</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Urology, Asklepios Hospital Barmbek, Hamburg</wicri:regionArea><placeName><settlement type="city">Hambourg</settlement><region type="land" nuts="2">Hambourg</region></placeName></affiliation></author><author><name sortKey="Pohlmann, Laura" sort="Pohlmann, Laura" uniqKey="Pohlmann L" first="Laura" last="Pohlmann">Laura Pohlmann</name></author><author><name sortKey="Herrmann, Thomas R W" sort="Herrmann, Thomas R W" uniqKey="Herrmann T" first="Thomas R W" last="Herrmann">Thomas R W. Herrmann</name></author><author><name sortKey="Gross, Andreas J" sort="Gross, Andreas J" uniqKey="Gross A" first="Andreas J" last="Gross">Andreas J. Gross</name></author><author><name sortKey="Bach, Thorsten" sort="Bach, Thorsten" uniqKey="Bach T" first="Thorsten" last="Bach">Thorsten Bach</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="doi">10.1111/j.1464-410X.2011.10767.x</idno><idno type="RBID">pubmed:22085294</idno><idno type="pmid">22085294</idno><idno type="wicri:Area/PubMed/Corpus">000408</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000408</idno><idno type="wicri:Area/PubMed/Curation">000408</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000408</idno><idno type="wicri:Area/PubMed/Checkpoint">000408</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000408</idno><idno type="wicri:Area/Ncbi/Merge">000516</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">120-W 2-µm thulium:yttrium-aluminium-garnet vapoenucleation of the prostate: 12-month follow-up.</title><author><name sortKey="Netsch, Christopher" sort="Netsch, Christopher" uniqKey="Netsch C" first="Christopher" last="Netsch">Christopher Netsch</name><affiliation wicri:level="3"><nlm:affiliation>Department of Urology, Asklepios Hospital Barmbek, Hamburg, Germany. c.netsch@asklepios.com</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Urology, Asklepios Hospital Barmbek, Hamburg</wicri:regionArea><placeName><settlement type="city">Hambourg</settlement><region type="land" nuts="2">Hambourg</region></placeName></affiliation></author><author><name sortKey="Pohlmann, Laura" sort="Pohlmann, Laura" uniqKey="Pohlmann L" first="Laura" last="Pohlmann">Laura Pohlmann</name></author><author><name sortKey="Herrmann, Thomas R W" sort="Herrmann, Thomas R W" uniqKey="Herrmann T" first="Thomas R W" last="Herrmann">Thomas R W. Herrmann</name></author><author><name sortKey="Gross, Andreas J" sort="Gross, Andreas J" uniqKey="Gross A" first="Andreas J" last="Gross">Andreas J. Gross</name></author><author><name sortKey="Bach, Thorsten" sort="Bach, Thorsten" uniqKey="Bach T" first="Thorsten" last="Bach">Thorsten Bach</name></author></analytic><series><title level="j">BJU international</title><idno type="eISSN">1464-410X</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Humans</term><term>Lasers, Solid-State (adverse effects)</term><term>Lasers, Solid-State (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Prostate (pathology)</term><term>Prostatic Hyperplasia (diagnosis)</term><term>Prostatic Hyperplasia (pathology)</term><term>Prostatic Hyperplasia (surgery)</term><term>Thulium</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Humains</term><term>Hyperplasie de la prostate ()</term><term>Hyperplasie de la prostate (anatomopathologie)</term><term>Hyperplasie de la prostate (diagnostic)</term><term>Lasers à solide (effets indésirables)</term><term>Lasers à solide (usage thérapeutique)</term><term>Mâle</term><term>Prostate (anatomopathologie)</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Thulium</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Thulium</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Lasers, Solid-State</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Hyperplasie de la prostate</term><term>Prostate</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Prostatic Hyperplasia</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Hyperplasie de la prostate</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Lasers à solide</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Prostate</term><term>Prostatic Hyperplasia</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Prostatic Hyperplasia</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Lasers, Solid-State</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Lasers à solide</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Humains</term><term>Hyperplasie de la prostate</term><term>Mâle</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Thulium</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Study Type - Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Thulium VapoEnucleation of the prostate (ThuVEP) has been introduced as a minimally invasive treatment modality of benign prostate obstruction (BPO). This study reports the largest series of patients with symptomatic BPO undergoing ThuVEP. Efficacy of this procedure was confirmed by prostate volume and PSA measurements at 12-month follow up, which have not been reported after ThuVEP so far.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22085294</PMID><DateCreated><Year>2012</Year><Month>06</Month><Day>13</Day></DateCreated><DateCompleted><Year>2012</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1464-410X</ISSN><JournalIssue CitedMedium="Internet"><Volume>110</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jul</Month></PubDate></JournalIssue><Title>BJU international</Title><ISOAbbreviation>BJU Int.</ISOAbbreviation></Journal><ArticleTitle>120-W 2-µm thulium:yttrium-aluminium-garnet vapoenucleation of the prostate: 12-month follow-up.</ArticleTitle><Pagination><MedlinePgn>96-101</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1464-410X.2011.10767.x</ELocationID><Abstract><AbstractText Label="UNLABELLED">Study Type - Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Thulium VapoEnucleation of the prostate (ThuVEP) has been introduced as a minimally invasive treatment modality of benign prostate obstruction (BPO). This study reports the largest series of patients with symptomatic BPO undergoing ThuVEP. Efficacy of this procedure was confirmed by prostate volume and PSA measurements at 12-month follow up, which have not been reported after ThuVEP so far.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the safety and efficacy of 120-W 2-µm thulium:yttrium-aluminium-garnet (YAG) vapoenucleation of the prostate (ThuVEP) for patients with symptomatic benign prostatic obstruction.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">In total, 207 consecutive patients undergoing ThuVEP at our institution were evaluated prospectively. ThuVEP was carried out using the 120-W 2-µm continuous-wave Tm:YAG laser. The enucleated tissue was then morcellated within the bladder. Patient demographic, perioperative and 12-month follow-up data were analysed. The complications were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean preoperative prostate volume was 57.8 ± 31.5 mL. Total operation duration averaged 64.9 ± 29.9 min, and the enucleation time was 36.5 ± 20.1 min. The mean catheter time was 2.2 ± 0.6 days. Thirteen (6.28%) patients required a second-look operation in the immediate postoperative course (failed morcellation n= 1, clot retention n= 4, residual tissue at the apex of the prostate n= 8). Four patients needed blood transfusions (1.93%) postoperatively. In all, 147 (71%) patients were available for review at the 12-month follow-up mark. Quality of life (4.4 ± 1.3 vs 1.2 ± 1.1), international prostate symptom score (21.9 ± 7.2 vs 5.1 ± 4), maximum urinary flow rate (9.4 ± 3.8 vs 23.5 ± 10.9 mL/s), postvoiding residual urine (159.2 ± 153.2 vs 26.7 ± 38.3 mL), prostate-specific antigen (5.0 ± 5.2 vs 0.6 ± 0.5 ng/mL) and prostate volume (57.8 ± 31.5 vs 10.7 ± 4.4 mL) changed significantly (P= 0.000). Median prostate-specific antigen reduction and prostate volume reduction were 87% and 80% respectively at follow-up. Urethral stricture and bladder neck contracture developed in 1.45% and 1.93% respectively of the patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">120-W ThuVEP is a safe and efficacious procedure for the treatment of symptomatic benign prostatic obstruction. The incidence of complications with ThuVEP was low.</AbstractText><CopyrightInformation>© 2011 BJU INTERNATIONAL.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Netsch</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Urology, Asklepios Hospital Barmbek, Hamburg, Germany. c.netsch@asklepios.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pohlmann</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Herrmann</LastName><ForeName>Thomas R W</ForeName><Initials>TR</Initials></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Andreas J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Bach</LastName><ForeName>Thorsten</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>11</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BJU Int</MedlineTA><NlmUniqueID>100886721</NlmUniqueID><ISSNLinking>1464-4096</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8RKC5ATI4P</RegistryNumber><NameOfSubstance UI="D013932">Thulium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2013 Aug;190(2):626</RefSource><PMID Version="1">23845360</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>BJU Int. 2012 Jul;110(1):101</RefSource><PMID Version="1">22085314</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D053844">Lasers, Solid-State</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011467">Prostate</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011470">Prostatic Hyperplasia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013932">Thulium</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="aheadofprint"><Year>2011</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-410X.2011.10767.x</ArticleId><ArticleId IdType="pubmed">22085294</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country><region><li>Hambourg</li></region><settlement><li>Hambourg</li></settlement></list><tree><noCountry><name sortKey="Bach, Thorsten" sort="Bach, Thorsten" uniqKey="Bach T" first="Thorsten" last="Bach">Thorsten Bach</name><name sortKey="Gross, Andreas J" sort="Gross, Andreas J" uniqKey="Gross A" first="Andreas J" last="Gross">Andreas J. Gross</name><name sortKey="Herrmann, Thomas R W" sort="Herrmann, Thomas R W" uniqKey="Herrmann T" first="Thomas R W" last="Herrmann">Thomas R W. Herrmann</name><name sortKey="Pohlmann, Laura" sort="Pohlmann, Laura" uniqKey="Pohlmann L" first="Laura" last="Pohlmann">Laura Pohlmann</name></noCountry><country name="Allemagne"><region name="Hambourg"><name sortKey="Netsch, Christopher" sort="Netsch, Christopher" uniqKey="Netsch C" first="Christopher" last="Netsch">Christopher Netsch</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/ThuliumV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000516 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000516 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Terre
|area= ThuliumV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:22085294
|texte= 120-W 2-µm thulium:yttrium-aluminium-garnet vapoenucleation of the prostate: 12-month follow-up.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:22085294" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ThuliumV1
| This area was generated with Dilib version V0.6.21. |  |